| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 154, Issue 11 5885-5895, Copyright © 1995 by American Association of Immunologists
ARTICLES |
PM Wallace, JN Rodgers, GM Leytze, JS Johnson and PS Linsley
Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA.
We have examined the ability of CTLA4Ig to induce long-lasting Ag- specific tolerance to a T-dependent Ag. Treatment of mice with murine CTLA4Ig following immunization with SRBC induced immune unresponsiveness to SRBC that was only reversible upon repeated Ag exposure. This unresponsiveness was Ag specific, lasted > 90 days, was observed in thymectomized mice, and was maintained even during challenge with another strong T-dependent Ag. A third challenge with SRBC, however, led to an Ab response. Splenic T cells and B cells from unresponsive mice were functional upon transfer to irradiated hosts, indicating that they had been neither depleted nor rendered permanently "tolerant" by CTLA4Ig. The mechanism of immunosuppression by CTLA4Ig was investigated by measuring cytokine transcripts in spleens of immunized mice. CTLA4Ig treatment following primary immunization blocked the induction of IL-2 transcripts in splenic T cells and IL-4 transcripts in both T cells and non-B, non-T cells. Splenocytes from CTLA4Ig-treated, SRBC-unresponsive mice showed altered induction of IL- 2 and IL-4 transcripts, but T cells nonetheless became primed for IL-4 mRNA synthesis despite the lack of a measurable Ab response. Anti-IL-4 mAb and human CTLA4Ig were synergistic in their ability to induce unresponsiveness, indicating that incomplete suppression of IL-4 production by CTLA4Ig limited its effectiveness.
This article has been cited by other articles:
|
|
 |
|
  M Dall'Era and J Davis CTLA4Ig: a novel inhibitor of costimulation Lupus, May 1, 2004; 13(5): 372 - 376. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Ardjomand, J. C. McAlister, N. J. Rogers, P. H. Tan, A. J. T. George, and D. F. P. Larkin Modulation of Costimulation by CD28 and CD154 Alters the Kinetics and Cellular Characteristics of Corneal Allograft Rejection Invest. Ophthalmol. Vis. Sci., September 1, 2003; 44(9): 3899 - 3905. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Lang, P. Nguyen, R. Peach, W. C. Gause, and C. S. Via In Vivo CD86 Blockade Inhibits CD4+ T Cell Activation, Whereas CD80 Blockade Potentiates CD8+ T Cell Activation and CTL Effector Function J. Immunol., April 15, 2002; 168(8): 3786 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Comer, W. J. King, N. Ardjomand, S. Theoharis, A. J. T. George, and D. F. P. Larkin Effect of Administration of CTLA4-Ig as Protein or cDNA on Corneal Allograft Survival Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 1095 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. TIKKANEN, K. B. LEMSTROM, and P. K. KOSKINEN Blockade of CD28/B7-2 Costimulation Inhibits Experimental Obliterative Bronchiolitis in Rat Tracheal Allografts . Suppression of Helper T Cell Type1-dominated Immune Response Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. I. Daikh and D. Wofsy Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide J. Immunol., March 1, 2001; 166(5): 2913 - 2916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Guillot, P. Mathieu, H. Coathalem, B. Le Mauff, M. G. Castro, L. Tesson, C. Usal, T. Laumonier, S. Brouard, J.-P. Soulillou, et al. Tolerance to Cardiac Allografts Via Local and Systemic Mechanisms After Adenovirus-Mediated CTLA4Ig Expression J. Immunol., May 15, 2000; 164(10): 5258 - 5268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Qian, M. Collins, A. H. Sharpe, and L. W. Hoyer Prevention and treatment of factor VIII inhibitors in murine hemophilia A Blood, February 15, 2000; 95(4): 1324 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Wallace, J. F. MacMaster, K. A. Rouleau, T. J. Brown, J. K. Loy, K. L. Donaldson, and A. F. Wahl Regulation of Inflammatory Responses by Oncostatin M J. Immunol., May 1, 1999; 162(9): 5547 - 5555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Judge, Z. Wu, X.-G. Zheng, A. H. Sharpe, M. H. Sayegh, and L. A. Turka The Role of CD80, CD86, and CTLA4 in Alloimmune Responses and the Induction of Long-Term Allograft Survival J. Immunol., February 15, 1999; 162(4): 1947 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Halbert, T. A. Standaert, C. B. Wilson, and A. D. Miller Successful Readministration of Adeno-Associated Virus Vectors to the Mouse Lung Requires Transient Immunosuppression during the Initial Exposure J. Virol., December 1, 1998; 72(12): 9795 - 9805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Schweitzer and A. H. Sharpe Studies Using Antigen-Presenting Cells Lacking Expression of Both B7-1 (CD80) and B7-2 (CD86) Show Distinct Requirements for B7 Molecules During Priming Versus Restimulation of Th2 But Not Th1 Cytokine Production J. Immunol., September 15, 1998; 161(6): 2762 - 2771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Guerder, E. E. Eynon, and R. A. Flavell Autoimmunity Without Diabetes in Transgenic Mice Expressing {beta} Cell-Specific CD86, But Not CD80: Parameters that Trigger Progression to Diabetes J. Immunol., September 1, 1998; 161(5): 2128 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Overwijk, A. Tsung, K. R. Irvine, M. R. Parkhurst, T. J. Goletz, K. Tsung, M. W. Carroll, C. Liu, B. Moss, S. A. Rosenberg, et al. gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of "Self"-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand J. Exp. Med., July 20, 1998; 188(2): 277 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Toellner, S. A. Luther, D. M.-Y. Sze, R. K.-W. Choy, D. R. Taylor, I. C.M. MacLennan, and H. Acha-Orbea T Helper 1 (Th1) and Th2 Characteristics Start to Develop During T Cell Priming and Are Associated with an Immediate Ability to Induce Immunoglobulin Class Switching J. Exp. Med., April 20, 1998; 187(8): 1193 - 1204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. M. Van Oosterhout, C. L. Hofstra, R. Shields, B. Chan, I. Van Ark, P. M. Jardieu, and F. P. Nijkamp Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of Allergic Asthma Am. J. Respir. Cell Mol. Biol., September 1, 1997; 17(3): 386 - 392. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. A. Kay, L. Meuse, A. M. Gown, P. Linsley, D. Hollenbaugh, A. Aruffo, H. D. Ochs, and C. B. Wilson Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver PNAS, April 29, 1997; 94(9): 4686 - 4691. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
